Hsbc Holdings PLC Reduces Position in Agenus Inc. (NASDAQ:AGEN)

Hsbc Holdings PLC decreased its stake in shares of Agenus Inc. (NASDAQ:AGEN – Get Rating) by 29.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 31,565 shares of the biotechnology company’s stock after selling 13,112 shares during the period. Hsbc Holdings PLC’s holdings in Agenus were worth $67,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Trellus Management Company LLC purchased a new position in shares of Agenus during the 3rd quarter worth $1,230,000. Virtu Financial LLC acquired a new position in shares of Agenus during the 3rd quarter valued at about $157,000. Los Angeles Capital Management LLC increased its stake in shares of Agenus by 32.3% during the 3rd quarter. Los Angeles Capital Management LLC now owns 1,092,218 shares of the biotechnology company’s stock valued at $2,239,000 after acquiring an additional 266,467 shares during the last quarter. Leisure Capital Management purchased a new stake in shares of Agenus during the 3rd quarter valued at $26,000. Finally, Prudential Financial Inc. lifted its stake in shares of Agenus by 7,745.3% in the 3rd quarter. Prudential Financial Inc. now owns 1,387,835 shares of the biotechnology company’s stock valued at $2,846,000 after purchasing an additional 1,370,145 shares in the last quarter. 53.81% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on AGEN. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Agenus in a research note on Tuesday, February 28th. EF Hutton Acquisition Co. I began coverage on shares of Agenus in a research note on Thursday, December 22nd. They issued a “buy” rating and a $8.30 price target for the company. Finally, StockNews.com downgraded Agenus from a “hold” rating to a “sell” rating in a research note on Monday, November 14th. One equities research analyst has rated the stock with a sell rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, Agenus has an average rating of “Moderate Buy” and an average price target of $7.10.

Agenus Trading Down 9.1 %

Shares of AGEN stock opened at $1.50 on Monday. Agenus Inc. has a 1-year low of $1.25 and a 1-year high of $3.37. The company has a market capitalization of $457.22 million, a price-to-earnings ratio of -1.85 and a beta of 1.50. The stock’s fifty day simple moving average is $2.34 and its 200-day simple moving average is $2.47.

About Agenus

(Get Rating)

Agenus, Inc is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H.